BioCryst Pharmaceuticals Inc (BCRX) is a publicly traded Healthcare sector company. As of August 25, 2026, BCRX trades at $9.74 with a market cap of $2.44B and a P/E ratio of -6.72. BCRX moved +0.64% today. Year to date, BCRX is +24.10%; over the trailing twelve months it is +13.08%. Its 52-week range spans $6.00 to $11.31. Analyst consensus is strong buy with an average price target of $20.44. Rallies surfaces BCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for BCRX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $9.74 |
| Market Cap | $2.44B |
| P/E Ratio | -6.72 |
| EPS | $-1.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.31 |
| 52-Week Low | $6.00 |
| Volume | 2.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $940.61M |
| Net Income | $-384.67M |
| Gross Margin | 97.78% |
9 analysts cover BCRX: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.44.